|
Protocol ID
|
Trial Title
|
UCLA-0306083, CDR0000335434; NCT00072072 |
A Phase I Clinical Trial of Celecoxib and Erlotinib in Patients with Stage IIIb or IV Non-Small Cell Lung Cancer |
08-008; NCT00629798 |
A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) |
CDR0000547155, WSU-2006-119; NCT00482846 |
Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma |
0704-19 IUCRO-0184; NCT00593554 |
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation (HSCT) Using Highly Purified CD34 Cells in Patients With Hematological Malignancies |
Hx-CD20-409; NCT00494780 |
An Open Labeled, Randomized, Two-Dose, Parallel Group Trial of Ofatumumab in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma. |
110927; NCT00823719 |
A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination With ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation |
110913; NCT00824265 |
A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide Versus Fludarabine-Cyclophosphamide Combination in Patients With Relapsed Chronic Lymphocytic Leukemia |
CDR0000593360; CAN-LRCC-UWOREB13877; WYETH-CAN-LRCC-UWOREB13877; NCT00659568 |
A Phase I Study of Temsirolimus in Combination With Metformin in Advanced Solid Tumours |
07-0444; NCT00703625 |
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies |
CDR0000619329; NCCTG-N078D; NCT00787969 |
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL) |
ONC-2005-001; EUDRACT 2005-004569-40; NCT00289809 |
A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma |
09-002; NCT00869999 |
Everolimus in Combination With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma |
07-BRE-43-NP; NCT00570921 |
A Phase II Study of Combined Fulvestrant (Faslodex) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure |
CRAD001J2301; EUDRACT Number: 2008-006556-21; NCT00876395 |
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HEr2 Positive Locally Advanced or Metastatic Breast Cancer |
CDR0000594429; CASE-2407; NCT00671112 |
A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Indolent and Mantle Cell Non-Hodgkin's Lymphoma |
10405; AVF3955s; CRAD001CUS2468; NCT00574769 |
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer |
GOA-TCOV; NCT00976183 |
A Phase I/II, Open Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer |
2009-0283; NCT01002755 |
Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) |
CDR0000593527; MAYO-MC0616; NCT00662636 |
Phase I Trial of the Combination of Dasatinib and Lapatinib |
